U.S. markets close in 3 hours 24 minutes
  • S&P 500

    4,155.51
    -18.34 (-0.44%)
     
  • Dow 30

    34,286.52
    -95.61 (-0.28%)
     
  • Nasdaq

    13,314.19
    -115.78 (-0.86%)
     
  • Russell 2000

    2,209.35
    -15.28 (-0.69%)
     
  • Crude Oil

    66.24
    +0.87 (+1.33%)
     
  • Gold

    1,867.30
    +29.20 (+1.59%)
     
  • Silver

    28.30
    +0.93 (+3.42%)
     
  • EUR/USD

    1.2158
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.6390
    +0.0040 (+0.24%)
     
  • GBP/USD

    1.4133
    +0.0031 (+0.22%)
     
  • USD/JPY

    109.1390
    -0.2080 (-0.19%)
     
  • BTC-USD

    43,202.17
    -4,146.07 (-8.76%)
     
  • CMC Crypto 200

    1,194.89
    -3.03 (-0.25%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of Viracta will present at the Oppenheimer 31st Annual Healthcare Conference taking place virtually from March 16-18, 2021. Viracta's management team will also be available for one-on-one investor meetings at the conference.

Presentation details can be found below.

Date:

Tuesday, March 16, 2021

Time:

2:30 p.m. ET

Webcast Link:

https://wsw.com/webcast/oppenheimer9/vira/2727098

A replay of the presentation will be archived for 90 days on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:

Company Contact:

Joyce Allaire

Dan Chevallard

LifeSci Advisors

Chief Operating Officer and Chief Financial Officer

jallaire@lifesciadvisors.com

dchevallard@viracta.com

(212) 915-2569

(858) 771-4193

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301245295.html

SOURCE Viracta